AI cancer detection gets a Rs. 128 crore boost as Infosys-backed 4baseCare closes Series B

June 12, 2026 | DailyAIWire.com | Startups & AI Health Desk

AI cancer care in India just got its largest vote of confidence this year.

Bengaluru startup 4baseCare closed its Series B at Rs. 128 crore (about $13.3 million) on Wednesday, with a fresh Rs. 38 crore tranche led by growX Ventures and Infosys.

The money has one job: scale OncoTwin, the company’s AI cancer platform that reads a tumor’s genetic code and tells oncologists which treatment is most likely to work for that exact patient.

Table of Contents

What is AI cancer care?

AI cancer care uses machine learning to analyze a patient’s tumor genome alongside real-world clinical records, then recommends treatments matched to that specific cancer.

Instead of standard chemotherapy for everyone, doctors get a tailored playbook per tumor.

4baseCare’s OncoTwin is one of the few platforms doing this for Indian and other non-Western patients.

The money trail

Stage	Amount	Lead Investors
Series B first close	Rs. 90 crore	Ashish Kacholia, Lashit Sanghvi, Yali Capital
Series B top-up (new)	Rs. 38 crore	growX Ventures, Infosys
Series B total	Rs. 128 crore (~$13.3M)	—
Infosys Innovation Fund (2024)	Rs. 8.3 crore (~$1M)	Infosys

CEO and co-founder Hitesh Goswami said the capital will expand the company’s genomics lab network globally and deepen OncoTwin’s clinical insights.

The flaw in global AI cancer models

Here is the part worth your attention.

Most genomic databases that train AI cancer tools were built on Caucasian patients.

growX founder Ashish Taneja pointed to “the underrepresentation of non-Caucasian populations in genomic datasets” as precision oncology’s biggest gap.

The consequence is practical, not academic.

An AI cancer model trained on Boston data can misjudge how a tumor in Patna, Dubai or Manila will respond to a drug.

4baseCare is building the dataset Western rivals don’t have — which makes this a data moat story, not just a funding story.

It also explains why Infosys has now invested twice.

Scaling from 1,500 to 10,000 tests a month

The company currently processes about 1,500 genomic tests monthly and is targeting 8,000 to 10,000 as new labs open. That is a 6x jump.

AI Cancer Test Volume (per month)

Now (2026)   ████                      1,500
Target       ████████████████████████  8,000-10,000  (~6x)

Expansion Plan	Detail
Labs running today	India, Dubai, Nepal, Philippines
New markets	8-10 countries in the next 12-18 months
Hospital partners	AIIMS Jammu, Max Healthcare, Shankara Hospital
Target regions	India, Middle East, Southeast Asia, Latin America

The in-hospital lab model matters most.

Sequencing happens on site instead of samples traveling to a central facility. For fast-moving cancers, cutting days off turnaround time changes outcomes, not just convenience.

Investors are circling oncology

4baseCare, founded in 2019 by Goswami and Kshitij Rishi, is part of a wider rush into cancer-focused startups:

Startup	Round	Amount
MOC Cancer Care & Research	Seed (Elevation Capital)	$18M
4baseCare	Series B	$13.3M
Everhope Oncology	Seed	$10M
ErlySign, OnCare, OneCell Diagnostics	Various	Funded

When seed rounds in cancer care hit $18 million, investors are saying India’s oncology infrastructure is underbuilt and they want in early.

The number to watch

A $13.3 million Series B is small by global biotech standards. The real test for AI cancer platforms in emerging markets is price, because most patients pay out of pocket. The 6x volume target only works if the cost per genomic test drops as labs scale. If 4baseCare’s next announcement is about cheaper tests rather than new countries, that is the stronger signal.